(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 29.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 80.59%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.89%.
Tg Therapeutics's revenue in 2025 is $454,068,000.On average, 2 Wall Street analysts forecast TGTX's revenue for 2025 to be $92,621,844,917, with the lowest TGTX revenue forecast at $91,155,139,990, and the highest TGTX revenue forecast at $94,088,708,509. On average, 3 Wall Street analysts forecast TGTX's revenue for 2026 to be $119,607,375,045, with the lowest TGTX revenue forecast at $109,891,962,229, and the highest TGTX revenue forecast at $129,217,275,227.
In 2027, TGTX is forecast to generate $156,244,375,746 in revenue, with the lowest revenue forecast at $140,374,799,799 and the highest revenue forecast at $168,375,948,516.